Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Blauvelt A, et al. Among authors: weisman j. Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9. Am J Clin Dermatol. 2017. PMID: 28074446 Free PMC article. Clinical Trial.
Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS. Gelfand JM, et al. Among authors: weisman jd. Arch Dermatol. 2012 Apr;148(4):487-94. doi: 10.1001/archdermatol.2012.370. Arch Dermatol. 2012. PMID: 22508874 Free PMC article.
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.
Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand JM. Yeung H, et al. Among authors: weisman jd. J Am Acad Dermatol. 2013 Jan;68(1):64-72. doi: 10.1016/j.jaad.2012.06.035. Epub 2012 Jul 28. J Am Acad Dermatol. 2013. PMID: 22846688 Free PMC article.
Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
Takeshita J, Wang S, Shin DB, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Robertson AD, Linn KA, Shinohara RT, Troxel AB, Van Voorhees AS, Gelfand JM. Takeshita J, et al. Among authors: weisman jd. J Am Acad Dermatol. 2014 Dec;71(6):1167-75. doi: 10.1016/j.jaad.2014.08.003. Epub 2014 Sep 24. J Am Acad Dermatol. 2014. PMID: 25260564 Free PMC article.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Blauvelt A, et al. Among authors: weisman j. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4. Lancet. 2017. PMID: 28478972 Clinical Trial.
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Blauvelt A, et al. Among authors: weisman j. Am J Clin Dermatol. 2018 Jun;19(3):457. doi: 10.1007/s40257-018-0353-x. Am J Clin Dermatol. 2018. PMID: 29600394 Free PMC article.
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE. Zouboulis CC, et al. Among authors: weisman j. J Am Acad Dermatol. 2019 Jan;80(1):60-69.e2. doi: 10.1016/j.jaad.2018.05.040. Epub 2018 Jun 1. J Am Acad Dermatol. 2019. PMID: 29860040 Clinical Trial.
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
Alexis AF, Rendon M, Silverberg JI, Pariser DM, Lockshin B, Griffiths CE, Weisman J, Wollenberg A, Chen Z, Davis JD, Li M, Eckert L, Gadkari A, Shumel B, Rossi AB, Graham NM, Ardeleanu M. Alexis AF, et al. Among authors: weisman j. J Drugs Dermatol. 2019 Aug 1;18(8):804-813. J Drugs Dermatol. 2019. PMID: 31424712 Clinical Trial.
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Guenther L, Potts Bleakman A, Weisman J, Poulin Y, Spelman L, Burge R, Erickson J, Todd K, Bertram CC, Ryan C. Guenther L, et al. Among authors: weisman j. Acta Derm Venereol. 2020 Jan 7;100(1):adv00006. doi: 10.2340/00015555-3353. Acta Derm Venereol. 2020. PMID: 31620802 Free PMC article. Clinical Trial.
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. Simpson EL, et al. Among authors: weisman j. JAMA Dermatol. 2020 Jan 1;156(1):44-56. doi: 10.1001/jamadermatol.2019.3336. JAMA Dermatol. 2020. PMID: 31693077 Free PMC article. Clinical Trial.
140 results